Premature ejaculation
Drug research and approvals for premature ejaculation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 20, 2026, 7 studies of premature ejaculation are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 7
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- Pelvic Floor Therapies for Lifelong Premature EjaculationNCT07627438 · Not applicable · Tanta University · starts Apr 26, 2026
- The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature EjaculationNCT07442396 · Not applicable · Uskudar University · starts Mar 1, 2026
- Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported…NCT07434271 · Phase 2 · Kadence Bio · starts Dec 1, 2025
- Proof of Concept Study on BP1.4979 Effect on Primary Premature EjaculationNCT07047404 · Phase 2 · Bioprojet · starts Sep 15, 2025
- Ejaculatory and Orgasmic Dysfunction RegistryNCT06605469 · Not reported · Charitable Union for the Research and Education of Peyronie's Disease · starts May 30, 2024
- Effectiveness and Safety of TENS Therapy for Premature EjaculationNCT06425224 · Phase 3 · Boston Medical Group · starts Jun 15, 2022
- Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.NCT06425211 · Not applicable · Boston Medical Group · starts Oct 30, 2021
Approved 2
- LidocaineSodium channel alpha subunit blocker
- Benzocaine
Phase 3 8
- DapoxetineSerotonin transporter inhibitor
- ClomipramineSerotonin transporter inhibitor
- TramadolMu opioid receptor agonist
- ParoxetineSerotonin transporter inhibitor
- TadalafilPhosphodiesterase 5A inhibitor
- TamsulosinAdrenergic receptor alpha-1 antagonist
- CyanocobalaminSupplement
- Folic acid
Phase 2 7
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- SildenafilPhosphodiesterase 5A inhibitor
- SilodosinAlpha-1a adrenergic receptor antagonist
- PrilocaineSodium channel alpha subunit blocker
- EpelsibanOxytocin receptor antagonist
- PagocloneGABA-A receptor; anion channel positive allosteric modulator
- DA-8031
Phase 1 or earlier 2
- GSK-958108
- EscitalopramSerotonin transporter inhibitor
How its trials ended
85 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 17 whose ending is known, 59% met their primary endpoint, 12% missed it and 29% stopped early.
- Completed, result not reported3946%
- Status unknown2024%
- Met its primary endpoint1012%
- Ongoing911%
- Missed its primary endpoint22%
- Stopped: enrollment or feasibility22%
- Stopped: other or unclear22%
- Stopped: sponsor or business decision11%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 15, 2013 | FortacinLidocaine; prilocaine | Recordati Ireland Ltd. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA